Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Additional Antiepileptic Mechanisms of Levetiracetam in Lithium-Pilocarpine Treated Rats

Abstract

Several studies have addressed the antiepileptic mechanisms of levetiracetam (LEV); however, its effect on catecholamines and the inflammatory mediators that play a role in epilepsy remain elusive. In the current work, lithium (Li) pretreated animals were administered LEV (500 mg/kg i.p) 30 min before the induction of convulsions by pilocarpine (PIL). Li-PIL-induced seizures were accompanied by increased levels of hippocampal prostaglandin (PG) E2, myeloperoxidase (MPO), tumor necrosis factor-α, and interleukin-10. Moreover, it markedly elevated hippocampal lipid peroxides and nitric oxide levels, while it inhibited the glutathione content. Li-PIL also reduced hippocampal noradrenaline, as well as dopamine contents. Pretreatment with LEV protected against Li-PIL-induced seizures, where it suppressed the severity and delayed the onset of seizures in Li-PIL treated rats. Moreover, LEV reduced PGE2 and MPO, yet it did not affect the level of both cytokines in the hippocampus. LEV also normalized hippocampal noradrenaline, dopamine, glutathione, lipid peroxides, and nitric oxide contents. In conclusion, alongside its antioxidant property, LEV anticonvulsive effect involves catecholamines restoration, as well as inhibition of PGE2, MPO, and nitric oxide.

Citation: Al-Shorbagy MY, El Sayeh BM, Abdallah DM (2013) Additional Antiepileptic Mechanisms of Levetiracetam in Lithium-Pilocarpine Treated Rats. PLoS ONE 8(10): e76735. https://doi.org/10.1371/journal.pone.0076735

Editor: Alice Y. W. Chang, Kaohsiung Chang Gung Memorial Hospital, Taiwan

Received: February 24, 2013; Accepted: August 28, 2013; Published: October 3, 2013

Copyright: © 2013 Al-Shorbagy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The work was individually funded by the three authors. These authors have no support or funding to report.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Levetiracetam (LEV) is a unique broad-spectrum second-generation antiepileptic drug (AED), which is used clinically as monotherapy or an add-on drug [1,2]. This AED is employed for partial onset/refractory seizures with or without secondary generalization, juvenile myoclonic seizures, and primary idiopathic generalized tonic-clonic seizures [2]. Experimentally, LEV antiepileptic effect has been documented in amygdala kindling, as well as genetic and spontaneous recurrent seizure models [3–5]. In status epilepticus (SE) model, LEV also delayed the onset of convulsive activity and reduced neuronal injury in pilocarpine (PIL) model, yet it did not affect the ictal discharge [6]. LEV antiepileptic effect resides in inhibition of excessive synchronized activity between neurons [2,7]. Unlike other AEDs, and by virtue of its novel structure, LEV suppresses calcium (Ca2+) mobilization from endoplasmic reticulum via binding to neuronal synaptic vesicle protein (SV) 2A [8,9]. Moreover, LEV indirectly impedes neuronal release of glutamate [10], consequently halting excitotoxicity and cellular injury [11]. Such effects are achieved by reducing high-voltage-activated Ca2+ current by blocking N- and P/Q-type Ca2+ channels [10,12] and suppressing rectifier potassium current [13] resulting in neuronal hyperpolarization. Directly, to maintain a dominant inhibitory environment, LEV affects GABA-receptor mediated currents and opposes the action of negative modulators of GABA and glycine receptors [14]. Furthermore, in kindled animals, LEV downregulates the overexpressed brain-derived neurotrophic factor and neuropeptide Y and increases neuropeptide Y1- and 5-like receptors [5], hence, preventing central modulation of seizure activity.

Inflammation has been implicated in epileptogenesis [15], where elevated levels of cytokines are associated with increased seizure susceptibility [16,17] imposing its role the initiation of neuronal excitability [18]. At the level of the blood brain barrier (BBB), tumor necrosis factor (TNF)-α contributes to the inflammatory response by increasing the expression of selectins and adhesion molecules to recruit leukocytes from the periphery, promoting their adhesion and entry into the CNS parenchyma [19,20]. Moreover, during the acute phase of SE, proinflammatory cytokines transcriptionally activate cyclooxygenase (COX)-2, and hence increases prostaglandin (PG) formation [21]. Free radicals produced during PGE2 synthesis, dopamine catabolism, and from activated infiltrated neutrophils might, in part, disrupt glutamate transporters increasing glutamate levels and thus increase seizure susceptibility [22–25]. Besides, catecholamines intimately control epileptic seizures [26,27], where noradrenaline was reported to sustain the activation of locus caeruleus neurons, which limit the spread of seizure during ictal initiation and/or propagation [27,28]. Furthermore, animals lacking a functional noradrenergic system are generally more susceptible to seizures, emphasizing the anticonvulsant role for endogenous noradrenaline [29]. In addition, increased synaptic dopamine concentration inhibits Ca2+ influx and suppresses seizure via the activation of D2 receptors to reduce N-type Ca2+ channels current [26,30–32]. However, to date, the mechanistic pathways of LEV to prevent early seizure onset of SE has not been fully delineated, therefore, the present study aimed to investigate the potential role of some inflammatory mediators, free radical-induced injury, as well as catecholamines on the LEV anticonvulsant effect using the lithium (Li)-PIL-induced seizure model in rats.

Material and Methods

1: Ethics Statement

The study was performed in accordance to the ethical procedures and policies approved by Animal Care and Use Committee of Faculty of Pharmacy, Cairo University and complies with the Guide for the Care and Use of Laboratory Animals [33].

2: Animals

Adult male Wistar rats (180±20 g) obtained from El Nile Pharmaceutical Company (Cairo, Egypt) were used. Rats were allowed one week acclimatization period at the animal facility of the Faculty of Pharmacy, Cairo University (Cairo, Egypt). Animals were housed in groups at constant temperature (23±2°C), humidity (60±10%), and a light/dark (12/12 h) cycle with lights on at 5:00 am. They were allowed free access to food and water throughout the experimental period. Seizure induction was done from 9 am to 12 pm to minimize circadian influences on seizure susceptibility.

3: Experimental design, seizure assessment, and tissue sampling

Rats were allocated into 3 groups of 12 animals each. In the first group, animals were given saline (i.p.) to serve as control group. In the other two groups rats received lithium chloride (LiCl3; 3 mEq/kg i.p.; Sigma-Aldrich, MO, USA) 20 h before the induction of convulsions by PIL (single i.p.; 150 mg/kg; Sigma-Aldrich, MO, USA) [34] or were administered LEV (500 mg/kg i.p.; Sigma-Aldrich, MO, USA) [35] 30 min before PIL to serve as Li-PIL non treated or LEV treated groups, respectively. Immediately after PIL injection, rats were placed singly in Plexiglas cages and were observed for 30 min. During the observation period, convulsive attacks were measured on Racine scale [36]: 0-behavioral arrest (motionless), hair raising, excitement, and rapid breathing; 1-mouth movements (lips and tongue), vibrissae movements, and salivation; 2-head and eye clonus; 3-forelimb clonus; “wet dog shakes”; 4-clonic rearing; 5-clonic rearing with loss of postural control and uncontrollable jumping. LEV treated animals that did not seize within the observation period were given a latency of 30 min. The median of the seizure stages for Li-PIL and LEV treated groups were calculated and the latency onset of the first seizure (stage 3-5), as well as the incidence of convulsing animals were recorded. Afterwards, each of the three groups was further divided into two subsets (n=6 rats). Animals were euthanized under deep ether anesthesia, brains were segregated and the two hippocampi were dissected. Hippocampi in the first subset were homogenized in ice cold saline for the estimation of cytokines, catecholamines, and redox biomarkers. In the second subset, one hippocampus was homogenized in hexadecyltrimethylammonium bromide (1%) in potassium phosphate buffer (100 mM, pH 6) for the determination of myeloperoxidase (MPO) activity, while the other was homogenized in 0.1 M phosphate buffer (pH 7.4), containing 1mM EDTA and 0.1 µM indomethacin for the PGE2 measurement. Homogenates were frozen at −80°C for subsequent analysis.

4: Determination of TNF-α, IL-10, PGE2, and catecholamines

Hippocampal TNF-α, interleukin (IL)-10, and PGE2 (R & D Systems, MN, USA), as well as noradrenaline and dopamine (Labor Diagnostika Nord GmbH & Co. KG; Nordhorn, Germany) were assessed using rat ELISA kits.

5: Determination of MPO activity

The enzyme activity was conducted according to the method of Bradley et al. [37], where hippocampal homogenates were subjected to 3 freeze/thaw cycles, 10 sec sonication, and 15 min 10,000×g 4°C centrifugation. o-Dianisidine hydrochloride (0.167%)/hydrogen peroxide (0.0005%) in phosphate buffer (50 mM, pH 6) were added to the supernatants. The absorbance rate was recorded at 460 nm.

6: Determination of glutathione

Glutathione was assessed using Ellman’s reagent as described by Beutler et al. [38]. Hippocampal homogenates were deproteinated with 5-sulfuosalicylic acid (10%) for 30 min at 4°C, centrifuged at 1000×g for 15 min at 4°C. 5,5′-Dithiobis-2-nitrobenzoic acid (1 mM) was added to the supernatant and the optical density was determined at 412 nm.

7: Determination of thiobarbituric acid reactive substances (TBARS)

The thiobarbituric acid reaction of Fee and Teitelbaum [39] was adopted for the estimation of lipid peroxides level, using malondialdehyde as a standard. To hippocampal homogenates, a 1:3 mixture of thiobarbituric acid (0.8%) and trichloroacetic acid (20%) were added and heated for 20 min at 100°C. After cooling, samples were centrifuged at 1000×g for 5 min and the absorbance of the TBARS in the supernatant was read at 535 nm.

8: Determination of nitric oxide

Nitric oxide content was quantified indirectly as nitrite/nitrate concentration using Griess reaction dependent method [40]. Hippocampal homogenates were deproteinated with zinc sulphate (30%) for 48 h at 4°C and centrifuged at 12,000×g for 15 min at 4°C. To the supernatant vanadium trichloride (0.8%) in 1 M HCl was added for the reduction of nitrate into nitrite, followed by the rapid addition of Griess reagent [N-(1-naphthyl)ethylenediamine dihydrochloride (0.1%) and sulfanilamide (2%) in HCl (5%)]. The mixture was incubated for 30 min at 37°C, allowed to cool, and the absorbance at 540 nm was determined.

9: Statistical analysis

For nonparametric data, values are median of 12 rats and statistical comparisons were analyzed using Kruskal–Wallis test (nonparametric one-way analysis of variance; ANOVA) followed by Dunn’s multiple comparisons test. For stage 3-5 seizure incidence, the Fisher’s exact probability test was used. Parametric data are expressed as mean (n=6) ± S.E.M. and statistical comparisons were carried out using one-way ANOVA followed by Student–Newman–Keuls multiple comparisons test. The minimal level of significance was identified at P<0.05.

Results

Table 1 shows that all Li-PIL treated rats exhibited seizure activity of Grade 3-5 within 5 min after PIL injection. This was manifested as bilateral forelimb myoclonus without (Grade 3) or with (Grade 4) rearing, or with loss of postural control (Grade 5). LEV successfully delayed the seizure latency to reach 27 min as compared to Li-PIL treated rats and profoundly attenuated seizure severity by 83% (Table 1).

GroupsMedian seizure stage (minimum – maximum)Stage 3 seizure latency (min)Stage 3 to 5 seizure incidence (%)
Li-PIL5 (3-5)*5.167±0.207a100*
LEV5001 (0-3)@26.958±2.069b16.7*,@

Table 1. Effect of Levetiracetam (LEV, 500 mg/kg i.p.) on lithium-pilocarpine (Li-PIL) -induced seizures in rats.

In the seizure stage, values are median of 12 rats; statistical comparisons were carried out using Kruskal–Wallis test (nonparametric ANOVA) followed by Dunn’s multiple comparisons test. In the parametric analysis (stage 3-5 seizure latency), values are means of 12 animals ± S.E.M.; statistical comparisons were carried out using one-way ANOVA followed by Student–Newman–Keuls multiple comparisons test. Stage 3-5 seizure incidence (12 animals) was compared using Fisher’s exact probability test as compared to control (*) and Li-PIL (@ groups, P<0.05.
CSV
Download CSV

Regarding the effect on catecholamines, Li-PIL decreased both noradrenaline and dopamine in the hippocampus by about 60% (Figure 1A and 1B), as compared to the control animals, effects that were opposed by LEV pretreatment. Moreover, the hippocampal PGE2 level was increased by 2.4 folds upon Li-PIL treatment, as compared to control rats. This effect was halted by LEV pre-administration (57%), as compared to Li-PIL treated animals (Figure 2A). Li-PIL model also elevated TNF-α by 145% (Figure 2B), IL-10 by 21% (Figure 2C), and MPO by 400% (Figure 2D) above the normal levels; however, pretreatment with LEV exerted no effect on the cytokines level, but normalized that of MPO. Furthermore, Li-PIL disrupted antioxidant/pro-oxidant balance in the hippocampus by decreasing glutathione (48%; Figure 3A) and elevating lipid peroxides (TBARS; 97%; Figure 3B), as well as nitric oxide (130%; Figure 3C). These effects were completely prevented by the pre-administration of LEV.

thumbnail
Download:
Figure 1. Effect of levetiracetam (LEV, 500 mg/kg i.p.) on hippocampal noradrenaline (NA; A) and dopamine (DA; B) in lithium-pilocarpine (Li-PIL)-induced convulsion in rats.

Values are means ± S.E.M. of 6 rats as compared to control (*) and Li-PIL (@) groups. Comparisons were carried out using one-way ANOVA followed by Student–Newman–Keuls Multiple Comparisons Test, P<0.05.

https://doi.org/10.1371/journal.pone.0076735.g001

thumbnail
Download:
Figure 2. Effect of levetiracetam (LEV, 500 mg/kg i.p.) on hippocampal prostaglandin (PG)E2 (A), tumor necrosis factor (TNF)-α (B), interleukin (IL)-10 activity (C), and myeloperoxidase (MPO) (D) in lithium-pilocarpine (Li-PIL)-induced convulsion in rats.

Values are means ± S.E.M. of 6 rats. As compared to control (*) and Li-PIL (@) groups. Comparisons were carried out using one-way ANOVA followed by Student–Newman–Keuls Multiple Comparisons Test, P<0.05.

https://doi.org/10.1371/journal.pone.0076735.g002

thumbnail
Download:
Figure 3. Effect of levetiracetam (LEV, 500 mg/kg i.p.) on hippocampal glutathione (GSH; A), thiobarbituric acid reactive substances (TBARS; B), and nitric oxide (NO; C) in lithium-pilocarpine (Li-PIL)-induced convulsion in rats.

Values are means ± S.E.M. of 6 rats. As compared to control (*) and Li-PIL (@) groups. Comparisons were carried out using one-way ANOVA followed by Student–Newman–Keuls Multiple Comparisons Test, P<0.05.

https://doi.org/10.1371/journal.pone.0076735.g003

Discussion

LEV Antiepileptic Efficacy Is Documented in Clinical as Well as in Experimental Settings Including Li-PIL SE Seizure Model [1,2,4–6]. The Current Investigation Demonstrates That LEV Prevents Li-PIL-Induced Seizures and Reduces the Ictal Incidence in about 80% of Animals. The Anticonvulsant Potential of LEV Involves the Preservation of Hippocampal Noradrenaline and Dopamine Levels, besides Anti-Inflammatory Activity via Inhibition of Neutrophil Recruitment (MPO) and PGE2 Synthesis in Li-PIL Treated Rats. In Addition, LEV Antioxidant Property, Detected Previously [27,28] and in the Present Work, Can Add Also to Its Anticonvulsant Effect

During convulsion, neuronal damage is induced by free radicals that are derived from different sources including activated infiltrated neutrophils [22], peroxynitrite formed from nitric oxide interaction with superoxide anion [41], as well as during PGE2 synthesis [23] and dopamine catabolism [24]. This investigation emphasized the previous findings, where we report elevated levels of MPO, signifying neutrophil infiltration, nitric oxide, and PGE2, along with a decrease in the dopamine level in the hippocampus of Li-PIL treated rats. In seized animals, increased free radicals formation is evidenced by the depletion of glutathione simultaneously with an increase of lipid peroxides, as reported in the current study. These effects are in line with previous studies reporting an imbalance in the redox status in association with seizure activity in PIL model [42,43].

In the present work, LEV antioxidant potential is evidenced by preserving hippocampal glutathione, as well as reducing nitric oxide and lipid peroxide levels. These findings coincide with those of Oliveira et al. [42] and Marini et al. [44], who showed that LEV protects against PIL and kainic acid-induced seizures via its antioxidant potential. Although LEV has no direct antioxidant effect, yet it enhances the effect of the endogenous antioxidants, viz., ascorbate and α-tocopherol [45], events that could account for the decreased lipid peroxidation and enriched glutathione pool in the hippocampus after LEV treatment as shown in the current study. In addition, the LEV-induced restoration of glutathione can be attributed to its up-regulating action on cystine/glutamate exchanger and hence increasing cysteine, the glutathione precursor [45]. Moreover, LEV-mediated inhibition of neutrophil recruitment offers an additional explanation for the reduced free radicals formation. Marchi et al. [46] reported a disruption in BBB permeability after Li-PIL administration that is sufficient to elicit seizures, an effect that aids in the neutrophil infiltration. The reduction in MPO by LEV could be linked to its ability to maintain the BBB integrity [47], where LEV preserves the morphological and functional properties of the BBB together with the reduction of pinocytotic activity during epileptic seizures [48].

Noradrenaline plays a crucial role in suppression of seizure activity, since its depletion increases seizure susceptibility and enhances epileptogenesis [49,50]. Previous studies revealed that agents that normalize noradrenaline exert antiepileptic efficacies [51,52], results that confirm the present findings. The enhancement of noradrenaline by the anticonvulsant could be attributed to increased synthesis and/or reduction in its metabolism as previously elucidated in a PIL seizure model [52], a fact that may entail the effect of LEV on dopamine. Notably, β2 adrenergic receptor activation increases hippocampal dopamine level that stimulates D2 receptor to prevent epileptogenesis [53,54]. Meanwhile, the activation of α1A adrenergic receptor increases hippocampal GABA to inhibit limbic seizures [54]. The latter event aggregates additively to halt excitotoxicity [55] giving a further insight to the anticonvulsant effect of LEV.

Suppression of excitotoxicity by LEV is reflected in the current investigation by the reduction in hippocampal PGE2 and nitric oxide. These excitotoxicity hallmarks were altered following Li-PIL administration that corroborate with previous findings [42,56,57]. Both free radicals and TNF-α transcriptionally up-regulate COX-2 to form PGE2 during which reactive oxygen species are produced [21,23,58]. LEV-mediated inhibition of PGE2 may be linked to inhibition of glutamate release [10], LEV-induced antioxidant activity and/or noradrenaline enhancement, rather than the suppression of TNF-α, which was not affected by LEV in this study. The AED neither exerts its anticonvulsant effect via modulation of TNF-α nor its counter partner IL-10 that is adaptively elevated during epileptogenesis induced by Li-PIL as previously reported [15,59].

Taken all together, besides abrogating oxidative/nitroactive stress, LEV anticonvulsant effect is additionally attributed to normalization of noradrenaline and dopamine, inhibition of PGE2 and MPO.

Author Contributions

Conceived and designed the experiments: MYAS BMES DMA. Performed the experiments: MYAS DMA. Analyzed the data: MYAS DMA. Contributed reagents/materials/analysis tools: MYAS DMA BMES. Wrote the manuscript: MYAS DMA.

References

  1. 1. Aiguabella M, Falip M, Villanueva V, de la Peña P, Molins A et al. (2011) Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational study. Seizure 20: 60-64. S1059-1311. doi:https://doi.org/10.1016/j.seizure.2010.10.009. PubMed: 21145758. 10)00240-2 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.seizure.2010.10.009.
  2. 2. Lyseng-Williamson KA; Lyseng-Williamson KA (2011) Levetiracetam: a review of its use in epilepsy. Drugs 71: 489-514. 7. PubMed: 21395360. PII];10.2165/11204490-000000000-00000 [doi]. PubMed: 21395360.
  3. 3. Glien M, Brandt C, Potschka H, Löscher W (2002) Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43: 350-357. doi:https://doi.org/10.1046/j.1528-1157.2002.18101.x. PubMed: 11952764. 18101 . PII.
  4. 4. Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C (1995) Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22: 207-213. doi:https://doi.org/10.1016/0920-1211(95)00077-1. PubMed: 8991787. 0920121195000771 . PII.
  5. 5. Husum H, Bolwig TG, Sánchez C, Mathé AA, Hansen SL (2004) Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav 5: 204-215. doi:https://doi.org/10.1016/j.yebeh.2003.12.004. PubMed: 15123022. S1525505003003962 . PII.
  6. 6. Zheng Y, Moussally J, Cash SS, Karnam HB, Cole AJ (2010) Intravenous levetiracetam in the rat pilocarpine-induced status epilepticus model: behavioral, physiological and histological studies. Neuropharmacology 58: 793-798. S0028-. doi:https://doi.org/10.1016/j.neuropharm.2009.12.007. PubMed: 20026136. 3908(09)00373-6 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.neuropharm.2009.12.007.
  7. 7. Meehan AL, Yang X, Yuan LL, Rothman SM (2012) Levetiracetam has an activity-dependent effect on inhibitory transmission. Epilepsia 53: 469-476. doi:https://doi.org/10.1111/j.1528-1167.2011.03392.x. PubMed: 22292611.
  8. 8. Janz R, Goda Y, Geppert M, Missler M, Südhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24: 1003-1016. S0896- doi:https://doi.org/10.1016/S0896-6273(00)81046-6. PubMed: 10624962. 6273(00)81046-6 . PII.
  9. 9. Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P et al. (2008) SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54: 715-720. S0028-. doi:https://doi.org/10.1016/j.neuropharm.2007.11.021. PubMed: 18207204. 3908(07)00380-2 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.neuropharm.2007.11.021.
  10. 10. Lee CY, Chen CC, Liou HH (2009) Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. Br J Pharmacol 158: 1753-1762. doi:https://doi.org/10.1111/j.1476-5381.2009.00463.x. PubMed: 19888964. BPH463 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1111/j.1476-5381.2009.00463.x.
  11. 11. Ueda Y, Doi T, Nagatomo K, Tokumaru J, Takaki M et al. (2007) Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Res 1151: 55-61. S0006-. doi:https://doi.org/10.1016/j.brainres.2007.03.021. PubMed: 17408599. 8993(07)00606-3 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.brainres.2007.03.021.
  12. 12. Niespodziany I, Klitgaard H, Margineanu DG (2001) Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 306: 5-8: S0304-S3940. PubMed: 11403944. 01)01884-5 . PII.
  13. 13. Zhang ZH, Lee YT, Rhodes K, Wang K, Argentieri TM et al. (2003) Inhibitory effects of pimozide on cloned and native voltage-gated potassium channels. Brain Res. Mol Brain Res 115: 29-38. doi:https://doi.org/10.1016/S0169-328X(03)00175-X. PubMed: 12824052. S0169328X0300175X . PII.
  14. 14. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S et al. (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136: 659-672. doi:https://doi.org/10.1038/sj.bjp.0704766. PubMed: 12086975.
  15. 15. Vezzani A, Granata T (2005) Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 46: 1724-1743. doi:https://doi.org/10.1111/j.1528-1167.2005.00298.x. PubMed: 16302852. EPI298 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1111/j.1528-1167.2005.00298.x.
  16. 16. Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A et al. (2008) A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain 131: 3256-3265. doi:https://doi.org/10.1093/brain/awn271. PubMed: 18952671. awn271 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1093/brain/awn271.
  17. 17. Voutsinos-Porche B, Koning E, Kaplan H, Ferrandon A, Guenounou M et al. (2004) Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy. Neurobiol Dis 17: 385-402. S0969-. doi:https://doi.org/10.1016/j.nbd.2004.07.023. PubMed: 15571975. 9961(04)00170-6 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.nbd.2004.07.023.
  18. 18. Vezzani A, French J, Bartfai T, Baram TZ (2011) The role of inflammation in epilepsy. Nat. Rev Neurol 7: 31-40. doi:https://doi.org/10.1038/nrneurol.2010.178. nrneurol.2010.178 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1038/nrneurol.2010.178.
  19. 19. Luster AD, Alon R, von Andrian UH (2005) Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 6: 1182-1190. doi:https://doi.org/10.1038/ni1275. PubMed: 16369557. ni1275 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1038/ni1275.
  20. 20. Ransohoff RM, Kivisäkk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3: 569-581. doi:https://doi.org/10.1038/nri1130. PubMed: 12876559. nri1130 . PII.
  21. 21. Mark KS, Trickler WJ, Miller DW (2001) Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther 297: 1051-1058. PubMed: 11356928.
  22. 22. Amantea D, Nappi G, Bernardi G, Bagetta G, Corasaniti MT (2009) Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J 276: 13-26. doi:https://doi.org/10.1111/j.1742-4658.2008.06766.x. PubMed: 19087196. EJB6766 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1111/j.1742-4658.2008.06766.x.
  23. 23. Nogawa S, Zhang F, Ross ME, Iadecola C (1997) Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17: 2746-2755. PubMed: 9092596.
  24. 24. Olney JW, Zorumski CF, Stewart GR, Price MT, Wang GJ et al. (1990) Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson’s and Huntington’s diseases. Exp Neurol 108: 269-272. doi:https://doi.org/10.1016/0014-4886(90)90134-E. PubMed: 1972067.
  25. 25. Liang LP, Patel M (2004) Mitochondrial oxidative stress and increased seizure susceptibility in Sod2(-/+) mice. Free Radic Biol Med 36: 542-554. doi:https://doi.org/10.1016/j.freeradbiomed.2003.11.029. PubMed: 14980699. S0891584903008268 . PII.
  26. 26. Barczyński B, Buszewicz G, Łuszczki JJ, Bańka K, Tutaj K et al. (2011) Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. Eur J Pharmacol 650: 550-555. S0014-. doi:https://doi.org/10.1016/j.ejphar.2010.10.039. PubMed: 21034737. 2999(10)01064-2 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.ejphar.2010.10.039.
  27. 27. Fornai F, Ruffoli R, Giorgi FS, Paparelli A (2011) The role of locus coeruleus in the antiepileptic activity induced by vagus nerve stimulation. Eur J Neurosci 33: 2169-2178. doi:https://doi.org/10.1111/j.1460-9568.2011.07707.x. PubMed: 21535457.
  28. 28. el HG, Boutroy MJ, Nehlig A (1992) Effects of pentylenetetrazol-induced seizures on dopamine and norepinephrine levels and on glucose utilization in various brain regions of the developing rat. Int J Dev Neurosci 10: 301-311. doi:https://doi.org/10.1016/0736-5748(92)90019-V. PubMed: 1414443.
  29. 29. Szot P, Weinshenker D, White SS, Robbins CA, Rust NC et al. (1999) Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. J Neurosci 19: 10985-10992. PubMed: 10594079.
  30. 30. Hsu KS, Huang CC, Yang CH, Gean PW (1995) Presynaptic D2 dopaminergic receptors mediate inhibition of excitatory synaptic transmission in rat neostriatum. Brain Res 690: 264-268. doi:https://doi.org/10.1016/0006-8993(95)00734-8. PubMed: 8535848. 0006-8993(95)00734-8 . PII.
  31. 31. Page KM, Cantí C, Stephens GJ, Berrow NS, Dolphin AC (1998) Identification of the amino terminus of neuronal Ca2+ channel alpha1 subunits alpha1B and alpha1E as an essential determinant of G-protein modulation. J Neurosci 18: 4815-4824. PubMed: 9634547.
  32. 32. Yan Z, Song WJ, Surmeier J (1997) D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. J Neurophysiol 77: 1003-1015. PubMed: 9065864.
  33. 33. ILAR (1996) Guide for the Care and Use of Laboratory Animals. Washington, D.C.: National Academy Press.
    • 34. Tariq M, Ahmad M, Moutaery KA, Deeb SA (2008) Pentoxifylline ameliorates lithium-pilocarpine induced status epilepticus in young rats. Epilepsy Behav 12: 354-365. S1525-. doi:https://doi.org/10.1016/j.yebeh.2007.12.004. PubMed: 18203664. 5050(07)00449-0 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.yebeh.2007.12.004.
    • 35. Sliva J, Dolezal T, Prochazkova M, Votava M, Krsiak M (2008) Preemptive levetiracetam decreases postoperative pain in rats. Neuro Endocrinol Lett 29: 953-957. PubMed: 19112399. NEL290608A12 . PII.
    • 36. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32: 281-294. doi:https://doi.org/10.1016/0013-4694(72)90177-0. PubMed: 4110397.
    • 37. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206-209. doi:https://doi.org/10.1111/1523-1747.ep12506462. PubMed: 6276474.
    • 38. Beutler B, Duron O, Kelly BM (1963) Improved method for the determination of blood glutathione. J Lab Clin Med 61: 882-888. PubMed: 13967893.
    • 39. Fee JA, Teitelbaum HD (1972) Evidence that superoxide dismutase plays a role in protecting red blood cells against peroxidative hemolysis. Biochem Biophys Res Commun 49: 150-158. doi:https://doi.org/10.1016/0006-291X(72)90022-8. PubMed: 5077847. 0006-291X(72)90022-8 . PII.
    • 40. Miranda KM, Espey MG, Wink DA; Miranda KM, Espey MG, Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5: 62-71. doi:https://doi.org/10.1006/niox.2000.0319. PubMed: 11178938;S1089-8603(00)90319-7 [pii]. doi:10.1006/niox.2000.0319. PubMed: 11178938.
    • 41. Chuang YC, Chen SD, Lin TK, Chang WN, Lu CH et al. (2010) Transcriptional upregulation of nitric oxide synthase II by nuclear factor-kappaB promotes apoptotic neuronal cell death in the hippocampus following experimental status epilepticus. J Neurosci Res 88: 1898-1907. doi:https://doi.org/10.1002/jnr.22369. PubMed: 20155797.
    • 42. Oliveira AA, Almeida JP, Freitas RM, Nascimento VS, Aguiar LM et al. (2007) Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. Cell Mol Neurobiol 27: 395-406. doi:https://doi.org/10.1007/s10571-006-9132-y. PubMed: 17205390.
    • 43. Yu X, Shao XG, Sun H, Li YN, Yang J et al. (2008) Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus. Brain Res 1200: 146-158. S0006-. doi:https://doi.org/10.1016/j.brainres.2008.01.047. PubMed: 18289512. 8993(08)00086-3 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.brainres.2008.01.047.
    • 44. Marini H, Costa C, Passaniti M, Esposito M, Campo GM et al. (2004) Levetiracetam protects against kainic acid-induced toxicity. Life Sci 74: 1253-1264. doi:https://doi.org/10.1016/j.lfs.2003.08.006. PubMed: 14697408. S0024320503009962 . PII.
    • 45. Ueda Y, Doi T, Takaki M, Nagatomo K, Nakajima A et al. (2009) Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy. Brain Res 1266: 1-7. S0006-. doi:https://doi.org/10.1016/j.brainres.2009.02.040. PubMed: 19268434. 8993(09)00415-6 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.brainres.2009.02.040.
    • 46. Marchi N, Fan Q, Ghosh C, Fazio V, Bertolini F et al. (2009) Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis 33: 171-181. S0969-. doi:https://doi.org/10.1016/j.nbd.2008.10.002. PubMed: 19010416. 9961(08)00250-7 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.nbd.2008.10.002.
    • 47. Ahishali B, Kaya M, Orhan N, Arican N, Ekizoglu O et al. (2010) Effects of levetiracetam on blood-brain barrier disturbances following hyperthermia-induced seizures in rats with cortical dysplasia. Life Sci 87: 609-619. S0024-. doi:https://doi.org/10.1016/j.lfs.2010.09.014. PubMed: 20875430. 3205(10)00402-9 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.lfs.2010.09.014.
    • 48. Gurses C, Ekizoglu O, Orhan N, Ustek D, Arican N et al. (2009) Levetiracetam decreases the seizure activity and blood-brain barrier permeability in pentylenetetrazole-kindled rats with cortical dysplasia. Brain Res 1281: 71-83. S0006-. doi:https://doi.org/10.1016/j.brainres.2009.05.033. PubMed: 19464270. 8993(09)00996-2 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.brainres.2009.05.033.
    • 49. Jobe PC, Dailey JW, Wernicke JF (1999) A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 13: 317-356. PubMed: 11028680.
    • 50. Weinshenker D, Szot P (2002) The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol Ther 94: 213-233. doi:https://doi.org/10.1016/S0163-7258(02)00218-8. PubMed: 12113799. S0163725802002188 . PII.
    • 51. Chachua T, Bilanishvili I, Khizanishvili N, Nanobashvili Z (2010) Noradrenergic modulation of seizure activity. Georgian Med News: 34-39. PubMed: 20622273.
    • 52. Freitas RM, Jordán J, Feng D (2010) Lipoic acid effects on monoaminergic system after pilocarpine-induced seizures. Neurosci Lett 477: 129-133. S0304-. doi:https://doi.org/10.1016/j.neulet.2010.04.048. PubMed: 20433896. 3940(10)00509-4 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.neulet.2010.04.048.
    • 53. Alam AM, Starr MS (1993) Dopaminergic modulation of pilocarpine-induced motor seizures in the rat: the role of hippocampal D2 receptors. Neuroscience 53: 425-431. doi:https://doi.org/10.1016/0306-4522(93)90206-U. PubMed: 8098511. 0306-4522(93)90206-U . PII.
    • 54. Clinckers R, Zgavc T, Vermoesen K, Meurs A, Michotte Y et al. (2010) Pharmacological and neurochemical characterization of the involvement of hippocampal adrenoreceptor subtypes in the modulation of acute limbic seizures. J Neurochem 115: 1595-1607. doi:https://doi.org/10.1111/j.1471-4159.2010.07065.x. PubMed: 20969569.
    • 55. Scorza FA, Arida RM, Naffah-Mazzacoratti MG, Scerni DA, Calderazzo L et al. (2009) The pilocarpine model of epilepsy: what have we learned? An Acad Bras Cienc 81: 345-365. S0001- doi:https://doi.org/10.1590/S0001-37652009000300003. PubMed: 19722008. 37652009000300003 . PII.
    • 56. Bellissimo MI, Amado D, Abdalla DS, Ferreira EC, Cavalheiro EA et al. (2001) Superoxide dismutase, glutathione peroxidase activities and the hydroperoxide concentration are modified in the hippocampus of epileptic rats. Epilepsy Res 46: 121-128. doi:https://doi.org/10.1016/S0920-1211(01)00269-8. PubMed: 11463513. S0920121101002698 . PII.
    • 57. Naffah-Mazzacoratti MG, Bellíssimo MI, Cavalheiro EA (1995) Profile of prostaglandin levels in the rat hippocampus in pilocarpine model of epilepsy. Neurochem Int 27: 461-466. doi:https://doi.org/10.1016/0197-0186(95)80003-4. PubMed: 8574174. 019701869500053B . PII.
    • 58. Cai F, Li C, Wu J, Min Q, Ouyang C et al. (2007) Modulation of the oxidative stress and nuclear factor kappa B activation by theaflavin 3,3'-gallate in the rats exposed to cerebral ischemia-reperfusion. Folia Biol (Praha) 53: 164-172. PubMed: 17976306. FB2007A0024 . PII.
    • 59. Abdallah DM (2010) Anticonvulsant potential of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in pentylenetetrazole-induced acute seizures and kindling in mice. Brain Res 1351: 246-253. S0006-. doi:https://doi.org/10.1016/j.brainres.2010.06.034. PubMed: 20599832. 8993(10)01398-3 . PII Retrieved onpublished at whilst December year 1111 from . . doi:https://doi.org/10.1016/j.brainres.2010.06.034.